Bortezomib ocular toxicities: Outcomes with ketotifen
نویسندگان
چکیده
منابع مشابه
Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions
Ocular toxicities are among the most common adverse events resulting from targeted anticancer agents and are becoming increasingly relevant in the management of patients on these agents. The purpose of this study is to provide a framework for management of these challenging toxicities based on objective data from FDA labels and from analysis of the literature. All oncologic drugs approved by th...
متن کاملKetotifen and nocturnal asthma.
Patients with asthma often wheeze at night and they also become hypoxic during sleep. To determine whether ketotifen, a drug with sedative properties, is safe for use at night in patients with asthma, we performed a double blind crossover study comparing the effects of a single 1 mg dose of ketotifen and of placebo on arterial oxygen saturation (SaO2), breathing patterns, electroencephalographi...
متن کاملKetotifen in adult asthma.
The efficacy and adverse effects of ketotifen 1 mg twice daily and 2 mg twice daily were compared with placebo in 50 patients with atopic asthma in a multicentre, double-blind study. Ketotifen in the higher dosage caused a slight reduction in salbutamol usage and a modest improvement in breathing in patients not already receiving inhaled corticosteroids. The drug was ineffective in patients rec...
متن کاملOcular myocysticercosis: favorable outcomes with early diagnosis and appropriate therapy.
BACKGROUND Ocular myocysticercosis is rare and a high index of suspicion is required for its diagnosis. OBJECTIVE To describe clinical characteristics and treatment outcome of ocular myocysticercosis. CASES We describe a series of three patients who had different clinical presentations of ocular myocysticerocosis namely diplopia, restricted ocular motility and sub-conjunctival cyst. The tre...
متن کاملTrials with Late-Onset Toxicities
Traditional designs for phase I clinical trials require each patient (or small group of patients) to be completely followed before the next patient or group is assigned. In situations such as when evaluating late-onset effects of radiation or toxicities from chemopreventive agents, this may result in trials of impractically long duration. We propose a new method, called the time-to-event contin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 2019
ISSN: 0361-8609
DOI: 10.1002/ajh.25382